Innovatus Capital Partners
Description
Innovatus Capital Partners is an independent investment adviser and portfolio management firm based in New York, United States. The firm distinguishes itself by focusing on private credit, real estate, and other opportunistic strategies rather than traditional early-stage venture capital. As of mid-2023, Innovatus Capital Partners manages approximately $1.7 billion in assets under management (AUM), deploying capital across a diverse range of sectors and asset classes.
Their investment approach centers on providing tailored capital solutions to middle-market and commercial-stage companies. A significant component of their strategy includes their specialized Life Sciences Strategy, which offers debt and structured equity financing to companies with commercial products or those nearing commercialization. This focus allows them to support businesses with established revenue streams or clear paths to market, often through non-dilutive or less dilutive financing structures.
Innovatus Capital Partners' typical transactions involve substantial capital commitments, reflecting their focus on later-stage and asset-backed opportunities. For instance, they have provided significant debt facilities, such as a $50 million debt facility to Xtant Medical and a $100 million debt facility to Invivyd, illustrating their capacity for large-scale financing. These examples underscore that their 'check sizes' are considerably larger than those of typical early-stage venture capital firms, aligning with their private credit and structured finance mandate.
Investor Profile
Innovatus Capital Partners has backed more than 20 startups, with 1 new investments in the last 12 months alone. The firm has led 11 rounds, about 55% of its total and boasts 10 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Post Ipo Debt, Series D, Series C rounds (top funding stages).
- Majority of deals are located in United States.
- Strong thematic focus on Health Care, Biotechnology, Medical.
- Typical check size: $50M – $200M.
Stage Focus
- Post Ipo Debt (35%)
- Series D (15%)
- Series C (10%)
- Post Ipo Equity (10%)
- Series E (5%)
- Series H (5%)
- Series B (5%)
- Series F (5%)
- Debt Financing (5%)
- Series Unknown (5%)
Country Focus
- United States (100%)
Industry Focus
- Health Care
- Biotechnology
- Medical
- Medical Device
- Health Diagnostics
- Therapeutics
- Bioinformatics
- Genetics
- Cloud Computing
- Life Science
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
'/%3e%3cuse xlink:href='%23a' transform='rotate(144 450 300)'/%3e%3cuse xlink:href='%23a' transform='rotate(216 450 300)'/%3e%3cuse xlink:href='%23a' transform='rotate(288 450 300)'/%3e%3c/svg%3e)
